ZNF83 antibody targets the zinc finger protein 83 (ZNF83), a member of the Krüppel-associated box (KRAB) domain-containing zinc finger protein (ZNF) family. These proteins are characterized by tandem arrays of C2H2-type zinc finger motifs, which mediate sequence-specific DNA binding, and a KRAB domain that often recruits transcriptional repressor complexes. ZNF83. also known as ZKSCAN7. is implicated in transcriptional regulation, potentially influencing chromatin remodeling and gene silencing through interactions with epigenetic modifiers like histone deacetylases (HDACs) or methyltransferases. It is thought to play roles in cellular differentiation, development, and oncogenesis, though its precise biological functions remain under investigation.
Antibodies against ZNF83 are primarily used as research tools to study its expression patterns, subcellular localization, and interactions in various tissues or disease models. They enable detection via techniques such as Western blotting, immunofluorescence, or chromatin immunoprecipitation (ChIP). Studies have explored ZNF83's involvement in cancer progression, stem cell regulation, and immune responses. For instance, altered ZNF83 expression has been observed in certain tumors, suggesting potential roles as a biomarker or therapeutic target. Commercial ZNF83 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within its N-terminal KRAB domain or C-terminal zinc finger regions. Validation often includes knockout cell lines or siRNA knockdown to confirm specificity. Researchers should consider cross-reactivity with homologous ZNF family members and verify antibody performance in their experimental systems.